BARRANQUILLA, Colombia– Procaps Group (NASDAQ: PROC), a leading integrated international healthcare and pharmaceutical company, today announced the appointment of Melissa Angelini as Investor Relations Director, effective February 1, 2022.
Melissa Angelini is a seasoned executive with over 15 years of experience in capital markets and investor relations with healthcare and pharmaceutical companies. She has extensive experience with clients in Latin American countries including Brazil, Mexico, Argentina, Chile, Colombia and Peru. Previously she was Innovation & Investor Relations Officer at Blau Farmacêutica, a Brazilian multinational pharmaceutical company with a USD 1 billion market capitalization. Angelini was also LATAM Head of Alliance Management & Investor Relations at GBT Grupo Biotoscana, a Latin American healthcare company. There she co-led the IPO of Grupo Biotoscana in 2017 through a deal that was approximately 5x oversubscribed and raised BRL 1.342B (USD $429M). This was the largest healthcare IPO in Latin America since 2011 and the largest healthcare IPO in the Americas in 2017. She was also Investor Relations Client Executive Manager at MZ Group, the world’s largest independent investor relations company, where she was responsible for the Investor Relations and Strategic Partnerships Department and managed some of the largest accounts in Latin America. Melissa holds an MBA in Finance from Insper Instituto de Ensino e Pesquisa, Brazil, and is fluent in English, Spanish and Portuguese.
“Melissa brings a broad range of investor relations and capital markets experience at pharma companies that will benefit Procaps as we accelerate the delivery of our innovative pharmaceutical solutions and drive new expansion initiatives. Importantly, this new position will eventually be based out of our Aventura, FL location as we expand our footprint in the U.S.,” said Patricio Vargas, Procaps Group CFO. “Melissa is a deeply experienced and respected investor relations professional, and her expertise working to communicate our strategy and growth opportunities externally will be instrumental as we continue to strengthen our investor and industry relationships with key stakeholders.”
Angelini added, “I am honored to be joining Procaps at such an exciting inflection point for the company. With their recent entrance to the U.S. on Nasdaq, and announcement of expanded production capacity in the U.S., I will be highly focused on communicating the Procaps story to a broadening group of worldwide investors and shareholders.”
